Uh, if you can give us a summary of the results of these, uh, uh, agents in patients with non-small cell lung cancer.

It's becoming a nice area in this population, particularly as you tell, uh, we have to test particularly for the HER2 mutation to either HER2 overexpression by immunohistochemistry.

Uh, I think the most important nowadays are the actionable genomic alterations of the HER2 mutation, particularly on the tyrosine kinase domain.

We k- know there is different type of mutation.

It can be tyrosine kinase domain, the transmembrane, and the extra part of the receptor.

But nowadays, the most important and approval are based on these tyrosine kinase, uh, mutations, particularly insertion on exon twenty, uh, YVMA, for example.

Uh, so nowadays, uh, we have two major possibility.

What, uh, do you select the appropriate treatment in each individual patient with HER2 mutations?